Melanoma: anti-IL-8 monoclonal antibody plus nivolumab,Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for,MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy,MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy,image_53046130-debe-4764-931f-